Updated: Novartis axes PhIII peanut allergy trial, expects to test ‘optimized dosing’ in new trial later this year

No­var­tis has again culled a late-stage tri­al of a bi­o­log­ic that it once thought could suc­ceed Xo­lair, its Genen­tech-part­nered an­ti-in­flam­ma­to­ry treat­ment for asth­ma and oth­er in­di­ca­tions.

The Swiss Big Phar­ma ter­mi­nat­ed a Phase III tri­al of lige­lizum­ab in pa­tients with peanut al­ler­gy, ac­cord­ing to a Jan. 16 up­date to the fed­er­al clin­i­cal tri­als data­base out­lin­ing the 52-week, ran­dom­ized study. The move comes af­ter an axe last Jan­u­ary in chron­ic in­ducible ur­ticaria (CIn­dU), an in­flam­ma­to­ry skin con­di­tion in which itchy welts and/or swelling goes on for more than six weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.